A Phase 3 interventional study of HRS9531 and Placebo in Subjects With Moderate-to-severe OSA and Obesity Who Are on PAP Therapy, sponsored by Fujian Shengdi Pharmaceutical Co., Ltd.. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by Fujian Shengdi Pharmaceutical Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing ribupatide in Obesity — 2 open to participants now, 9 under way, 6 of them phase 3. ribupatide · Obesity.
Among the 16 studies testing ribupatide in Obesity, this one is the 8th largest by enrollment, is one of 8 that started in 2025, is one of 7 in phase 3, and was the 9th registered.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
Browse Obesity studies →2 of the 16 studies testing ribupatide in Obesity are open now, in 2 countries. Recruiting first, the newest first:
Kailera · Sites in United States
Ages 18–85 · Healthy volunteers
Fujian Shengdi Pharmaceutical Co., Ltd. · Sites in China
Ages 18–75
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2023; this study’s year is marked. 8 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 144 is above the median of 67 across 9,023 interventional studies indexed under Obesity.
Median enrollment 142 across the 16 interventional studies. Of the 7 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 16 have an industry lead sponsor. The 3 most frequent:
This study is registered under Fujian Shengdi Pharmaceutical Co., Ltd., one of the names counted as Jiangsu HengRui Medicine Co., Ltd.. Under that name alone:
Fujian Shengdi Pharmaceutical Co., Ltd. is the lead sponsor of 66 studies on the registry; 24 are open to participants now.
24 studies in Obesity by Jiangsu HengRui Medicine Co., Ltd.: 8 open now, 13 under way, 4 of them phase 3. Of 10 finished, 0 (0%) have results posted.
Among the 24 studies in Obesity by Jiangsu HengRui Medicine Co., Ltd., this one is the 11th largest by enrollment, is one of 10 that started in 2025, is one of 6 in phase 3, reaches primary completion later than 1 of the 12 other live ones, and was the 14th registered.
Jiangsu HengRui Medicine Co., Ltd.’s Obesity studies by the year they started, since 2021.
4 of the studies testing ribupatide in Obesity that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06994650Phase 3Fujian Shengdi Pharmaceutical Co., Ltd.A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Who Are on Positive Airway Pressure Ventilation (PAP) Therapy | 2026-12 |
| NCT06974851Phase 3Fujian Shengdi Pharmaceutical Co., Ltd.A Phase III Study Evaluating the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity | 2026-12 |
| NCT07285902Phase 3Fujian Shengdi Pharmaceutical Co., Ltd.A Study Comparing the Efficacy and Safety of HRS9531 Injection With Semaglutide Injection in Subjects With Obesity | 2027-03 |
| NCT07458269KaileraEfficacy and Safety of Ribupatide (KAI-9531) Administered Once Weekly in Participants Living With Obesity Who Do Not Have Diabetes | 2027-05 |
Add all 4 to your calendar (.ics) → With an account.
Among the 16 studies testing ribupatide in Obesity, from their registry updates:
Among Jiangsu HengRui Medicine Co., Ltd.’s 24 in Obesity:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is a phase 3 clinical trial, aiming to evaluate the efficacy and safety of HRS-9531 injection in obese subjects with obstructive sleep apnea (OSA) who are on positive airway pressure ventilation (PAP) therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: HRS9531
Drug: Placebo
HRS9531 will be administered by Subcutaneous injection
Matching Placebo will be administered by Subcutaneous injection
The change of AHI form baseline after 52 weeks of treatment
Time frame: 52 weeks
The percentage change in AHI from baseline after 52 weeks of treatment
Time frame: 52 weeks
The percentage of subjects with ≥50% AHI reduction from baseline after 52 weeks of treatment;
Time frame: 52 weeks
The percentage of subjects with AHI <5.0 events /h, or AHI ranging from 5.0 to 14.0 events/h and Epworth Sleepiness Scale (ESS) ≤10 after 52 weeks of treatment;
Time frame: 52 weeks
The percent change in body weight from baseline after 52 weeks of treatment.
Time frame: 52 weeks
Plan to share: Undecided
No publications or documents are linked to this record.
Started Aug 2025 (actual). Primary completion is estimated for Dec 2026, 16 months after the start.
Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's planned 16 months is below that.
Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ribupatide
Fujian Shengdi Pharmaceutical Co., Ltd. →